Skip to main content


Chief Executive Officer

Dan Spira was a former Vice President at Valeant Pharmaceuticals from 2011 to 2015. This included being based in Australia as the Managing Director of iNova Pharmaceuticals and Bausch + Lomb from 2011 to 2014 and then in North America with responsibility for a portfolio of Valeant owned companies.  Prior to that he spent 15 years at Johnson & Johnson in various roles including VP, Country Manager and Chief Marketing Officer.

Dan has now relocated back to Australia and returned as CEO of the iNova group.

Our regional leaders are responsible for all Sales, Marketing, Local Supply Chain and Regulatory functions within their countries


Managing Director – Australia and New Zealand

Andrew joined iNova in 2019 from GSK Consumer Healthcare, where he was General Manager of the joint venture with Pfizer in Australia and New Zealand. Prior to that, Andrew was General Manager for Pfizer Consumer Healthcare ANZ. Andrew has also held leadership roles at Bayer, MSD and Novartis, and is a Director on the Board of Consumer Healthcare Products Australia. Andrew has worked across both Consumer Health and Prescription categories, in Sales & Marketing roles, and has had experience outside the ANZ market via local roles in South Africa and also regional roles spanning Asia and Latin America.


President of Asia

Sacha has more than 16 years of healthcare industry experience in finance, corporate strategy and development, and general management spanning Asia, Europe and USA. This experience includes Vice President roles at DKSH managing the Vietnam and Myanmar markets. Prior to that, Sacha spent 14 years with Novartis including GM and Head of South Asia (with responsibility for 9 markets) as well as Director of Strategy, Business Development & Licencing for Developing Markets (Asia, Middle East, Africa and Russia)


Managing Director Africa

Kym has been leading the iNova South Africa business since 2013 and prior to that was in General Management positions at Adcock Ingram.

At a corporate level, we have the following functions ‘Centres of Excellence’ that support our country teams and also work on future business growth initiatives.



Chief Operating Officer

Paul joined iNova in May 2022 as Chief Operating Officer having previously spent 28 years with GlaxoSmithKline/Haleon working across a range of operational, strategic and leadership roles for both the Pharmaceutical and Consumer Healthcare business units. Key positions included, VP International Markets Quality & Supply Chain, VP, Head of Global Manufacturing, VP, Oral Care Supply Chain. Paul holds an MBA from Imperial College London, and a BSc in Environmental Chemistry. Paul lives in Singapore.



Executive Director – Business Development and M&A

Luke joined iNova in 2023 to lead the Mergers & Acquisitions (M&A) and Business Development (BD) functions. Luke has over 20 years’ experience in corporate finance and mergers and acquisitions roles specialising in the consumer, retail and healthcare sectors. Prior to joining iNova, Luke had an extensive career in investment banking advising clients on M&A, strategic initiatives, capital structure, financing and equity capital markets spanning transactions across Asia Pacific, Europe and the US.


General Counsel and Head of Communications

Kate joins us from Mundipharma where she has most recently been head of Legal & Compliance for their Australian business. Prior to Mundipharma, Kate was in senior legal roles at Novartis, Fairfax and was a lawyer at Mallesons.


Executive Director – Portfolio Strategy & Innovation

Filomena is an experienced OTC and Pharma commercial leader with 25 year experience across organisations including Pfizer and Johnson & Johnson in senior roles such as Marketing Director and OTC Franchise leader. Filomena has a track record of success in building iconic brands and product pipeline across markets for major brands such as Zyrtec, Benadryl, Sudafed, Codral, Listerine and Nicorette. Her most recent role has been Director of Business Development & Marketing for ASMI (Australia Self Medicated Industry Association) where she has had the opportunity to have a seat at the table representing all of the key industry players as they drive and shape the future OTC market landscape.


Chief Financial Officer

William joined iNova in 2024. He has over 20 years of global financial experience, many of which were at private equity portfolio companies. Prior to joining iNova, William held senior financial leadership roles in multi-national FMCG and professional service companies including LUXASIA, Everise and Knowledge Universe. William is a Chartered Accountant of Singapore.


Chief People Officer

Yee Leng joined iNova in 2024. She is a dynamic leader with over 25 years of HR experience across a broad range of industries including pharmaceutical, healthcare, banking and technology. Prior to joining iNova, Yee Leng held senior global and regional leadership roles in a number of multinational companies including ASM International, Allergan, DBS Bank and Nokia Siemens among others.